📊 New late-stage clinical trial results show an investigational Lilly medicine reduced moderate-to-severe obstructive sleep apnea severity by an average 61 percent in adults living with obesity and OSA on the 9 mg dose — alongside meaningful weight loss. One medicine. Two connected conditions. A promising step toward treating obesity and certain complications together. See our press release at the link in bio. #ADA2026